• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

The Role of Osteopontin in Murine TRALI

July 11, 2019

Osteopontin (OPN) is a proinflammatory, multifunctional protein with both physiological and pathological roles. Since OPN attracts neutrophils, which are involved in the pathophysiology of transfusion-related acute lung injury (TRALI), researchers hypothesized that OPN may play a role in the development of TRALI. Using a murine TRALI model, OPN knock-out (KO) mice were not susceptible to TRALI compared to wild type mice. Intravenously injecting OPN into OPN KO mice restored the TRALI response and neutrophil accumulation in the lungs while using an anti-OPN antibody inhibited TRALI induction. TRALI induction was also dependent on macrophages and OPN polymerization but was not dependent the OPN receptor CD44, macrophage inflammatory protein-2 (MIP-2, the murine homolog of human IL-8), or interleukin-6 (IL-6). These data suggest that OPN recruits neutrophils to the lungs independent of MIP-2, IL-6 or other PMN attractants, and TRALI induction in humans may possibly be blocked by using anti-OPN antibodies.

Reference:

Kapur R, Kasetty G, Rebetz J, Egesten A, Semple JW. Osteopontin mediates murine transfusion-related acute lung injury via stimulation of pulmonary neutrophil accumulation.   Blood 2019; 134(1); 74-84.

Filed Under

  • Adverse Events (non-infectious)
  • News

Recommended

  • Genetic Variation in the Fc-gamma Receptor Gene is Associated with Protection against RBC Alloimmunization

  • Decreases in U.S. Blood Donors Despite Increases in Eligible Donors

  • Urgent Global Need of Blood Products

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Tranexamic Acid for Patients with Hematological Disorders

  • Interventions to Prevent Vasovagal Reactions among Blood Donors

  • Nipocalimab for Severe Hemolytic Disease of the Fetus and Newborn

  • Clinical Guidelines for Anemia and Chronic Kidney Disease

    Question of the Day

    Copyright © 2026 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley